Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy

Archives of Dermatology

Volumn 142, Issue 1, 2006, Pages 37-41

  Liu, Rosemarie H ^a   Albrecht, Joerg ^b   Werth, Victoria P ^b,c  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID;

ARTICLE; COHORT ANALYSIS; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; HUMAN; LONG TERM CARE; MEDICAL RECORD; MEDICAL SOCIETY; PATIENT REFERRAL; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; SAMPLE SIZE; SKIN DISEASE; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CROSS-SECTIONAL STUDIES; DENSITOMETRY, X-RAY; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; RETROSPECTIVE STUDIES; SKIN DISEASES; TIME FACTORS; TREATMENT OUTCOME;

EID: 30844467311     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.1.37     Document Type: Article

References (31)

1. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
2. Rehman Q, Lane NE. Effect of glucocorticoids on bone density. Med Pediatr Oncol. 2003;41:212-216.
3. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-787.
4. Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax. 1991;46:803-806.
5. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 1996;39:1791-1801.
6. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001;44:1496-1503.
7. Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med. 2003;163:2619-2624.
8. 3) for prevention of fractures in primary care. BMJ. 2005;330:1003.
9. Fosamax. PDR.net Web site. Available at: http://www.pdr.net/pdrnet/ librarian. Accessed January 25, 2005.
10. Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol. 2003;15:454-457.
11. Saag KG, Emkey R, Schnitzer TJ, et al; Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339:292-299.
12. Blair MM, Carson DS, Barrington R. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis. J Fam Pract. 2000;49:839-848.
13. Homik JE, Cranney A, Shea B, et al. A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol. 1999;26:1148-1157.
14. Liberman UA, Weiss SR, Broll J, et al; The Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437-1443.
15. Pols HA, Felsenberg D, Hanley DA, et al; Fosamax International Trial Study Group. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int. 1999;9:461-468.
16. Reid DM, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int. 2001;69:242-247.
17. WHO Study Group. Assessment of Fracture Risk and its Application to Screening for Post-menopausal Osteoporosis. Geneva, Switzerland: World Health Organization; 1994.
18. Peat ID, Healy S, Reid DM, Ralston SH. Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis. 1995;54:66-68.
19. Hart SR, Green B. Osteoporosis prophylaxis during corticosteroid treatment: failure to prescribe. Postgrad Med J. 2002;78:242-243.
20. Aagaard EM, Lin P, Modin GW, Lane NE. Prevention of glucocorticoid- induced osteoporosis: provider practice at an urban county hospital. Am J Med. 1999;107:456-460.
21. Mudano A, Allison J, Hill J, Rothermel T, Saag K. Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. J Rheumatol. 2001;28:1298-1305.
22. Buckley LM, Marquez M, Hudson JO, et al. Variation in physicians' judgments about corticosteroid induced osteoporosis by physician specialty. J Rheumatol. 1998;25:2195-2202.
23. Buckley LM, Marquez M, Feezor R, Ruffin DM, Benson LL. Prevention of corticosteroid-induced osteoporosis: results of a patient survey. Arthritis Rheum. 1999;42:1736-1739.
24. Solomon DH, Katz JN, La Tourette AM, Coblyn JS. Multifaceted intervention to improve rheumatologists' management of glucocorticoid-induced osteoporosis: a randomized controlled trial. Arthritis Rheum. 2004;51:383-387.
25. Naunton M, Peterson GM, Jones G, Griffin GM, Bleasel MD. Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis. J Rheumatol. 2004;31:550-556.
26. Yosipovitch G, Hoon TS, Leok GC. Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients. Arch Dermatol. 2001;137:477-481.
27. Bone Health and Osteoporosis: A Report of the Surgeon General. Office of the Surgeon General Web site. Available at: http://www.surgeongeneral.gov/ library/bonehealth/. Accessed December 21, 2004.
28. Actonel. PDR.net Web site. Available at: http://www.pdr.net/pdrnet/ librarian. Accessed January 25, 2005.
29. Saag KG. Prevention of glucocorticoid-induced osteoporosis. South Med J. 2004;97:555-558.
30. Franchimont N, Canalis E. Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease. Autoimmun Rev. 2003;2:224-228.
31. Cohen D, Adachi JD. The treatment of glucocorticoid-induced osteoporosis. J Steroid Biochem Mol Biol. 2004;88:337-349.